Thursday, 27 January 2011
David Brennan, Chief Executive Officer said:
"Our performance in 2010 underlines the strength and resilience of AstraZeneca’s business. Despite government pricing pressures and anticipated patent expiries in the US and Western Europe, our revenues remained in line with the previous year driven by excellent performance of our key brands and continued growth in Emerging Markets. This performance, combined with disciplined management of the business enabled us to deliver increased earnings, increase the dividend and return residual cash to shareholders through share repurchases."
Fourth quarter and full year results 2010
Announced on Thursday 27 January 2011
- Cautionary statement regarding forward looking statements (PDF 56kb)
- Narrative (PDF 495kb)
- Figures (PDF 590kb)
- Pipeline table (PDF 298kb)
Downloads
- Full Year Results presentation (PDF 935kb)
- David Brennan, Chief Executive Officer script (PDF 212kb)
- Martin Mackay, President R&D script (PDF 265kb)
- Simon Lowth, Chief Financial Officer script (PDF 264kb)